Elite in Glossectomy

Dr. Eben L. Rosenthal

Plastic Surgery | Otolaryngology
1301 22nd Ave S, 
Nashville, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Elite in Glossectomy
1301 22nd Ave S, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eben Rosenthal is a Plastic Surgeon and an Otolaryngologist in Nashville, Tennessee. Dr. Rosenthal is rated as an Elite provider by MediFind in Glossectomy. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Oral Cancer, Oral Squamous Cell Carcinoma, Laryngectomy, and Glossectomy. Dr. Rosenthal is currently accepting new patients.

His clinical research consists of co-authoring 257 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Glossectomy.

Specialties
Plastic Surgery
Otolaryngology
Licenses
Otolaryngology in AL
Hospital Affiliations
Vanderbilt University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

VANDERBILT UNIVERSITY MEDICAL CENTER
1301 22nd Ave S, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Pilot Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
Pilot Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
Enrollment Status: Recruiting
Publish Date: May 06, 2025
Intervention Type: Drug, Procedure
Study Drug: 111I-n Panitumumab
Study Phase: Phase 1
Pilot Study of 89Zr Panitumumab in Pancreas Cancer
Pilot Study of 89Zr Panitumumab in Pancreas Cancer
Enrollment Status: Withdrawn
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Zr-89 Panitumumab
Study Phase: Phase 1
Pilot Study Evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab for Dual-Modality Imaging for Nodal Staging in Head and Neck Cancer
Pilot Study Evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab for Dual-Modality Imaging for Nodal Staging in Head and Neck Cancer
Enrollment Status: Completed
Publish Date: May 19, 2023
Intervention Type: Device, Drug
Study Drugs: Panitumumab-IRDye800, Zirconium Zr-89 Panitumumab
Study Phase: Phase 1
A Phase II Study Evaluating Panitumumab-IRDye800 vs. Sentinel Node Biopsy and (Selective) Neck Dissection for Metastatic Lymph Node Identification in Patients With Head and Neck Cancer
A Phase II Study Evaluating Panitumumab-IRDye800 vs. Sentinel Node Biopsy and (Selective) Neck Dissection for Metastatic Lymph Node Identification in Patients With Head and Neck Cancer
Enrollment Status: Completed
Publish Date: November 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures
Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures
Enrollment Status: Completed
Publish Date: September 24, 2021
Intervention Type: Drug, Device
Study Phase: Phase 1
Open-Label Study Evaluating Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures
Open-Label Study Evaluating Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures
Enrollment Status: Terminated
Publish Date: March 31, 2020
Intervention Type: Procedure, Biological, Drug
Study Phase: Phase 1/Phase 2
Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Enrollment Status: Terminated
Publish Date: June 24, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

257 Total Publications

Fluorescence-Guided Surgery for Assessing Margins in Head and Neck Cancer: A Review.
Fluorescence-Guided Surgery for Assessing Margins in Head and Neck Cancer: A Review.
Journal: JAMA surgery
Published: June 18, 2025
Similar Doctors
Distinguished in Glossectomy
Dr. Sarah L. Rohde
Otolaryngology
Distinguished in Glossectomy
Dr. Sarah L. Rohde
Otolaryngology

Vanderbilt University Medical Center

1301 Medical Ctr Dr, 
Nashville, TN 
 (0.1 miles away)
615-322-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sarah Rohde is an Otolaryngologist in Nashville, Tennessee. Dr. Rohde is rated as a Distinguished provider by MediFind in Glossectomy. Her top areas of expertise are Tongue Cancer, Laryngeal Cancer, Throat Cancer, Glossectomy, and Laryngectomy. Dr. Rohde is currently accepting new patients.

Advanced in Glossectomy
Dr. Robert J. Sinard
Otolaryngology
Advanced in Glossectomy
Dr. Robert J. Sinard
Otolaryngology

Vanderbilt University Medical Center

719 Thompson Ln, 
Nashville, TN 
 (3.1 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Sinard is an Otolaryngologist in Nashville, Tennessee. Dr. Sinard is rated as a Distinguished provider by MediFind in Glossectomy. His top areas of expertise are Tongue Cancer, Acinic Cell Carcinoma of Salivary Glands, Adenoid Cystic Carcinoma, Glossectomy, and Laryngectomy. Dr. Sinard is currently accepting new patients.

Advanced in Glossectomy
Dr. Kyle Mannion
Otolaryngology | Pediatric Otolaryngology
Advanced in Glossectomy
Dr. Kyle Mannion
Otolaryngology | Pediatric Otolaryngology

Vanderbilt University Medical Center

719 Thompson Ln, 
Nashville, TN 
 (3.1 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kyle Mannion is an Otolaryngologist and a Pediatric Otolaryngologist in Nashville, Tennessee. Dr. Mannion is rated as a Distinguished provider by MediFind in Glossectomy. His top areas of expertise are Tongue Cancer, Laryngeal Cancer, Throat Cancer, Laryngectomy, and Thyroidectomy. Dr. Mannion is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosenthal's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile